{"protocolSection": {"identificationModule": {"nctId": "NCT01316315", "orgStudyIdInfo": {"id": "N6022-2A1-02"}, "organization": {"fullName": "Nivalis Therapeutics, Inc.", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma", "officialTitle": "A Double-Blind, Randomized, Placebo-Controlled, Two-Period, Cross-Over Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma"}, "statusModule": {"statusVerifiedDate": "2014-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-03"}, "primaryCompletionDateStruct": {"date": "2011-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-03-07", "studyFirstSubmitQcDate": "2011-03-15", "studyFirstPostDateStruct": {"date": "2011-03-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-01-28", "resultsFirstSubmitQcDate": "2014-01-28", "resultsFirstPostDateStruct": {"date": "2014-03-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-04-17", "lastUpdatePostDateStruct": {"date": "2014-05-05", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Nivalis Therapeutics, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine whether a single IV dose of N6022 will have a significant bronchoprotective effect, compared with placebo, during methacholine challenge.", "detailedDescription": "The number of patients with adverse events measured in both the treated and placebo groups from start of dosing until Day 28 post dose."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 14, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Active", "type": "EXPERIMENTAL", "description": "N6022 - 5 mg", "interventionNames": ["Drug: Active"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Active", "description": "A 5 mg single dose given intravenously via syringe pump over 1 minute.", "armGroupLabels": ["Active"], "otherNames": ["N6022"]}, {"type": "DRUG", "name": "Placebo", "description": "Same as active", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Measurement of Change in Methacholine PC20 From Baseline Compared With Placebo 24 Hours After Dosing", "description": "These assessments will be recorded at various times over the study - Methacholine PC20 at screening, and at 8, 24, 48 hours postdose and Day 7; spirometry assessments will be recorded at screening, at 2, 4, 6, 8, 24, 48 hours postdose and Day 7.", "timeFrame": "24 hours"}], "secondaryOutcomes": [{"measure": "Measurement of Change in Methacholine PC20 From Baseline Compared With Placebo 8 Hours After Dosing", "description": "These assessments will be recorded at various times over the study - Methacholine PC20 at screening, and at 8, 24, 48 hours postdose and Day 7; spirometry assessments will be recorded at screening, at 2, 4, 6, 8, 24, 48 hours postdose and Day 7.", "timeFrame": "8 hours"}, {"measure": "To Assess the Safety and Tolerability of Single Dose Administration of N6022 in Patients With Mild Asthma.", "description": "Adverse event (AE) reporting will begin upon signing of the consent and will continue until end-of-study (follow up phone call Day 28 +/- 2 days after dosing in the second treatment period). Number of patients with an adverse event will be documented and analyzed.", "timeFrame": "10 Weeks"}], "otherOutcomes": [{"measure": "Measurement of Change in Methacholine PC20 From Baseline Compared With Placebo After 7 Days of Dosing", "timeFrame": "7 Days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Body mass index (BMI) between 18.5 and 35 kg/m2, inclusive, at screening.\n* Patient has a \u2264 5 pack years smoking history and nonsmoking for \u2265 one year.\n* Documented history of mild bronchial asthma, first diagnosed at least 6 months and currently being treated only with intermittent short-acting beta-agonist therapy by inhalation.\n* Pre-bronchodilator FEV1 \u2265 75% of predicted at screening.\n* Sensitivity to methacholine with a provocation concentration of methacholine resulting in a 20% fall in FEV1 (PC20 methacholine) of \u2264 8 mg/ml at screening.\n* Demonstrated stable lung function during screening with \u226410% variability between two assessments of FEV1 taken at least 7 days apart at approximately the same time of day.\n\nExclusion Criteria:\n\n* Hypertension at screening is defined as systolic blood pressure (BP) \\>150 mmHg or diastolic BP \\> 90mmHg.\n* Respiratory tract infection and/or exacerbation of asthma within prior 4 weeks\n* History of life-threatening asthma\n* Administration of steroids within 4 weeks of the screening visit.\n* History of being unable to tolerate or complete MCh testing.\n* Blood donation (500 mL) within 3 months of starting the clinical study.\n* Tested positive for hepatitis C antibody or hepatitis B surface antigen.\n* Tested positive for human immunodeficiency virus (HIV) antibodies.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Rhohit K Katial, MD", "affiliation": "National Jewish Health", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Monica Kraft, MD", "affiliation": "Duke Asthma, Allergy and Airway Center", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "National Jewish Health", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Duke Asthma, Allergy and Airway Center", "city": "Durham", "state": "North Carolina", "zip": "27704", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}]}, "referencesModule": {"references": [{"pmid": "29642282", "type": "DERIVED", "citation": "Que LG, Yang Z, Lugogo NL, Katial RK, Shoemaker SA, Troha JM, Rodman DM, Tighe RM, Kraft M. Effect of the S-nitrosoglutathione reductase inhibitor N6022 on bronchial hyperreactivity in asthma. Immun Inflamm Dis. 2018 Jun;6(2):322-331. doi: 10.1002/iid3.220. Epub 2018 Apr 11."}], "seeAlsoLinks": [{"label": "Sponsor", "url": "http://n30pharma.com/"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Active", "description": "N6022 - Active 5 mg"}, {"id": "FG001", "title": "Placebo", "description": "Non-Active"}], "periods": [{"title": "Sequence 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Sequence 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Any patient that received a dose of N6022 or Placebo", "groups": [{"id": "BG000", "title": "Active", "description": "N6022 - 5 mg"}, {"id": "BG001", "title": "Placebo", "description": "Non-Active"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "14"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "14"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "description": "Any patient that received a dose of N6022 or placebo", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "12"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "11"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "13"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "14"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Measurement of Change in Methacholine PC20 From Baseline Compared With Placebo 24 Hours After Dosing", "description": "These assessments will be recorded at various times over the study - Methacholine PC20 at screening, and at 8, 24, 48 hours postdose and Day 7; spirometry assessments will be recorded at screening, at 2, 4, 6, 8, 24, 48 hours postdose and Day 7.", "populationDescription": "Any patient that received a dose of N6022 or placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/mL", "timeFrame": "24 hours", "groups": [{"id": "OG000", "title": "N6022", "description": "Patients received a single IV administration of 5 mL of N6022 on Day 1 in each treatment period and single dose of placebo on Day 1 of the second period."}, {"id": "OG001", "title": "Placebo", "description": "Patients received a single IV administration of 5 mL of placebo on Day 1 in each treatment period and single dose of N6022 on the day 1 of the second period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.48", "spread": ".093"}, {"groupId": "OG001", "value": "-0.2", "spread": "0.3"}]}]}]}, {"type": "SECONDARY", "title": "Measurement of Change in Methacholine PC20 From Baseline Compared With Placebo 8 Hours After Dosing", "description": "These assessments will be recorded at various times over the study - Methacholine PC20 at screening, and at 8, 24, 48 hours postdose and Day 7; spirometry assessments will be recorded at screening, at 2, 4, 6, 8, 24, 48 hours postdose and Day 7.", "populationDescription": "Any patient that received a dose of N6022 or Placebo", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/mL", "timeFrame": "8 hours", "groups": [{"id": "OG000", "title": "Active", "description": "N6022 - Active 5 mg"}, {"id": "OG001", "title": "Placebo", "description": "Non-Active"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "spread": "0.63"}, {"groupId": "OG001", "value": "-0.54", "spread": "0.33"}]}]}]}, {"type": "SECONDARY", "title": "To Assess the Safety and Tolerability of Single Dose Administration of N6022 in Patients With Mild Asthma.", "description": "Adverse event (AE) reporting will begin upon signing of the consent and will continue until end-of-study (follow up phone call Day 28 +/- 2 days after dosing in the second treatment period). Number of patients with an adverse event will be documented and analyzed.", "populationDescription": "Any patient that received a dose of N6022 or placebo", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Adverse Events", "timeFrame": "10 Weeks", "groups": [{"id": "OG000", "title": "Active", "description": "N6022 - Active 5 mg"}, {"id": "OG001", "title": "Placebo", "description": "Non-Active"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "9"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Measurement of Change in Methacholine PC20 From Baseline Compared With Placebo After 7 Days of Dosing", "populationDescription": "Any patient that received a dose of N6022 or Placebo", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/mL", "timeFrame": "7 Days", "groups": [{"id": "OG000", "title": "Active", "description": "N6022 - Active 5 mg"}, {"id": "OG001", "title": "Placebo", "description": "Non-Active"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.74", "spread": "1.01"}, {"groupId": "OG001", "value": "-0.38", "spread": ".68"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "8 Months", "description": "Patients were followed from signing consent through both sequences of the crossover design.", "eventGroups": [{"id": "EG000", "title": "Active", "description": "N6022 - Active 5 mg", "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 11, "otherNumAtRisk": 14}, {"id": "EG001", "title": "Placebo", "description": "Non-Active", "seriousNumAffected": 0, "seriousNumAtRisk": 13, "otherNumAffected": 9, "otherNumAtRisk": 13}], "otherEvents": [{"term": "Abdominal Pain Upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Injection Site Hematoma", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "administration and site conditions", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Blood Creatinine Increased", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Blood LDH", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Blood Phosphorous Decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 13}]}, {"term": "Blood Urine Present", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 13}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Nasal Turminate Abnormality", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Oropharyngeal Pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Pharyngeal Erthyma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Respiratory Fatigue", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Allergic Rhinnitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Erthyma", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Flushing", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Thrombophlebitis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Injection Site Erthyma", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "administration and site conditions", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Injection Site Induration", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "administration and site conditions", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Injection Site Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "administration and site conditions", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Tenderness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "administration and site conditions", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 13}]}, {"term": "ALT Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "AST Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Blood Bilirubin Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Back Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Muscle Spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Pain in Extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Thrombophlebitis Superficial", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The investigator agrees with the use of results of the clinical study for the purposes of national and international registration, publication, and information for medical and pharmaceutical professionals. If necessary, the competent authorities will be notified of the investigator's name, address, qualifications, and extent of involvement. An investigator shall not publish any data (poster, abstract, paper, etc.) without having consulted with the Sponsor in advance."}, "pointOfContact": {"title": "Janice M. Troha", "organization": "N30 Pharmaceuticals Inc.", "email": "janice.troha@n30pharma.com", "phone": "720-945-7714"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": true}